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Abstract 
NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine 
potency and safety testing methods, and to identify opportunities to advance new and improved methods that can further reduce, 
refine, and replace animal use (the 3Rs). Six topics were addressed in detail by speakers and workshop participants and are 
reported in a series of reports. This workshop report, the fifth in the series, addresses methods and strategies for human vaccine 
post-licensing safety testing that can reduce, refine, and replace animal use. It also provides recommendations for priority 
research and other activities necessary to advance the development and/or implementation of 3Rs methods for human vaccine 
post-licensing safety testing. Workshop participants agreed that future 3Rs activities should give highest priority to vaccine safety 
tests that (1) use the most animals per test and for which many vaccine lots are tested annually, (2) produce high variability 
and/or require frequent repeat tests, (3) are associated with severe animal pain and distress, and/or (4) involve nonhuman 
primates. Based on these criteria, safety tests for diphtheria, pertussis, oral polio, and tetanus vaccines were identified as the 
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highest priorities. Recommended priority research, development, and validation activities included (1) expanding use of the 
transgenic mouse model for oral polio vaccine, and (2) developing alternatives to the monkey neurovirulence test for preclinical 
safety and lot release neurovirulence testing of mumps vaccines. Implementation of the workshop recommendations is expected 
to advance alternative in vitro methods for human vaccine post-licensing safety testing that will benefit animal welfare while 
ensuring continued production of safe human vaccines and protection of human and animal health. 
 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the National Toxicology Program 
Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) 
Keywords: human vaccines; vaccine safety testing; vaccine potency testing; 3Rs alternatives; ICCVAM 
1. Introduction 
Vaccines contribute to improved animal and human health and welfare by preventing and controlling infectious 
diseases agents that can cause disease and death. However, the test methods necessary to ensure vaccine 
effectiveness and safety can involve subjecting large numbers of animals to significant pain and distress. In the 
United States, the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and 
the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods 
(NICEATM) promote the scientific validation and regulatory acceptance of test methods that accurately assess the 
safety of chemicals and products while reducing, refining (less or no pain and distress), and replacing animal use 
(3Rs). Accordingly, NICEATM and ICCVAM recently identified vaccine potency and safety testing as one of their 
four highest priorities [1].  
ICCVAM is an interagency committee of United States Federal agencies that is charged by law with evaluating 
new, revised, and alternative testing methods with regulatory applicability. ICCVAM members represent 15 U.S. 
Federal regulatory and research agencies that require, use, generate, or disseminate safety testing data. Member 
agencies include the Department of Agriculture (USDA), which regulates veterinary vaccines, and the Food and 
Drug Administration (FDA), which regulates human vaccines. ICCVAM is a permanent interagency committee of 
the National Institute of Environmental Health Sciences (NIEHS) under NICEATM. NICEATM administers 
ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts validation 
studies on promising new safety testing methods. NICEATM and ICCVAM serve a critical public health role in 
translating research advances from the bench into standardized safety test methods that can be used in regulatory 
practice to prevent disease and injury. 
To promote and advance the development and use of scientifically valid alternative methods for human and 
veterinary vaccine testing, NICEATM and ICCVAM organized the International Workshop on Alternative Methods 
to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing: State of the Science and 
Future Directions. The workshop was held at the National Institutes of Health in Bethesda, Maryland, on September 
14-16, 2010. It was organized in conjunction with the European Centre for the Validation of Alternative Methods 
(ECVAM), the Japanese Center for the Validation of Alternative Methods (JaCVAM), and Health Canada. 
The workshop addressed the state of the science and developed recommendations for future progress in three 
major areas: (1) in vitro replacement methods for potency testing; (2) reduction and refinement methods for potency 
testing; and (3) reduction, refinement, and replacement methods for vaccine safety testing [2]. Workshop reports 
were prepared for each of the three topics for human vaccines and for each of the three topics for veterinary 
vaccines. Each report, including this one, incorporates the contributions of invited experts and the general public 
during the various plenary presentations and dedicated breakout group sessions [3, 4, 5, 6, 8]. This report addresses 
methods and strategies for the reduction, refinement, and replacement of procedures requiring animal use for post-
licensing safety testing of human vaccines. 
2. Goals and organization of the workshop 
The goals of the international workshop were to (1) identify and promote the implementation of currently 
available and accepted alternative methods that can reduce, refine, and replace the use of animals in human and 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the National Toxicology  
Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).
Open access under CC BY-NC-ND license.
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veterinary vaccine potency and safety testing; (2) review the state of the science of alternative methods and identify 
knowledge and data gaps that need to be addressed; and (3) identify and prioritize research, development, and 
validation efforts needed to address these gaps in order to advance alternative methods that will also ensure 
continued protection of human and animal health. 
The workshop was organized with four plenary sessions and three breakout group sessions. In the breakout 
sessions, workshop participants: 
• Identified criteria to prioritize vaccine safety and potency tests for future alternative test method development and 
identified high priorities using these criteria 
• Reviewed the current state of the science of alternative methods and discussed ways to promote the 
implementation of available methods  
• Identified knowledge and data gaps that need to be addressed  
• Identified and prioritized research, development, and validation efforts needed to address these gaps in order to 
advance alternative methods while ensuring continued protection of human and animal health 
The workshop opened with a plenary session in which expert scientists and regulatory authorities from the United 
States, Europe, Japan, and Canada outlined the importance of vaccines to human and animal health [9, 10] and 
described national and international regulatory testing requirements for human and veterinary vaccines [2, 11, 12, 
13, 14, 15, 16]. Authorities emphasized that, following the approval of a vaccine, testing is required to ensure that 
each subsequent production lot is pure, safe, and potent enough to generate a protective immune response in people 
or animals [11, 12]. 
The second plenary session addressed methods that have been accepted and methods that are in development that 
do not require the use of animals for assessing the potency of vaccines [17, 18, 19, 20]. This was followed by 
breakout sessions to discuss the state of the science and recommendations for future progress for in vitro potency 
tests for human and veterinary vaccines. Workshop recommendations to advance the use and development of 
alternative methods that can replace animals for the potency testing of human [3] and veterinary vaccines [4] are 
available elsewhere in these proceedings. 
The third plenary session addressed (1) potency test methods that refine procedures to avoid or lessen pain and 
distress by incorporating earlier humane endpoints or by using antibody quantification tests instead of challenge 
tests and (2) methods and approaches that reduce the number of animals required for each test [21, 22, 23, 24, 24, 
25, 26, 27]. Breakout groups then discussed the state of the science and developed recommendations for future 
progress. Workshop recommendations to advance the use and development of alternative methods that can reduce 
and refine animal use for potency testing of human [5] and veterinary [6] vaccines are available elsewhere in these 
proceedings. 
The final plenary session addressed methods and approaches for reducing, refining, and replacing animal use to 
assess the safety of production lots of veterinary and human vaccines [11, 28, 29, 30]. Breakout groups then 
discussed the state of the science and developed recommendations for advancing alternative methods for vaccine 
safety testing. Workshop recommendations to advance the use and development of alternative methods for safety 
testing of veterinary vaccines are available in these proceedings [7], while recommendations for safety testing of 
human vaccines are provided in this paper.  
3. Requirements for human vaccine post-licensing safety testing  
For both human and veterinary vaccines, strict regulatory guidelines ensure that vaccines released for sale are 
pure, safe, potent, and effective [31]. Vaccine safety is ensured by extensive in-process and end-product testing, 
consistent manufacturing processes, and post-marketing surveillance. The post-licensing safety tests performed to 
support release of vaccine lots for clinical use include general safety tests to evaluate systemic toxicity associated 
with the vaccine or any of its components, and more specific tests such as: 
• Assessment for the presence of residual toxin and reversion of inactivated toxins to their active form 
• Neurovirulence tests for live attenuated vaccines (e.g., oral polio vaccine [OPV]) 
• Pyrogen tests  
• Tests for extraneous viral contamination of virus seed lots 
Due to the large number of animals used annually for safety testing of human vaccines, many regulatory agencies 
actively encourage the development and implementation of novel approaches that reduce, refine, and replace the use 
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of animals in vaccine safety testing. Tables 1 and 2 provide examples of alternative methods that have been 
successfully implemented for some of the required tests.  
 
Table 1: Examples of human vaccine safety tests that replace the use of animals 
 
Vaccine Product Available In Vitro Alternative Method 
Alternative Method 
References 
Traditional Safety 
Test 
Traditional Safety 
Test Reference 
All human vaccinesd GMP/consistency of 
manufacture (replacement) 
Schwanig et.al. 1997 
[36] 
General safety test in 
mice and guinea pigse
21 CFR 610.11 [35]; 
Japanese Minimum 
Requirements for 
Biological Products, 
2006 [33] 
Bacterins and Toxoids 
Diphtheria toxoid 
vaccine 
(Corynebacterium 
diphtheriae) 
Vero cell testa, b, c for 
residual toxin and 
reversion to toxicity 
(replacement) 
Ph. Eur. Monograph 
0443 [32] 
Guinea pig test Japanese Minimum 
Requirements for 
Biological Products, 
2006 [33]; 
WHO TRS 800, 
Annex 2, 1990 [34] 
Viral Vaccines 
Oral polio vaccine (live 
virus) 
Mutation analysis by PCR 
and restriction enzyme 
cleavage (MAPREC) test 
(type 3)f (replacement)  
Ph. Eur. Monograph 215 
[37]; WHO TRS 904, 
Annex 1, 2002 [38] 
Nonhuman primate 
neurovirulence test 
Japanese Minimum 
Requirements for 
Biological Products, 
2006 [33]; WHO TRS 
800, Annex 1, revised 
1989 [39] 
aPublished in the European Pharmacopoeia (Ph. Eur.).  
bValidated in Japan. 
cWHO Technical Report Series. 
d Licensed in the United States unless an exemption has been granted. 
e General safety tests in mice/guinea pigs not required in Europe for routine lot release testing.  
fValidated by the WHO for type 3 oral polio vaccine . 
4. Prioritizing vaccine safety tests for future research, development, and validation activities 
Although progress has been made in the introduction of alternative methods for post-licensing vaccine safety 
testing, many vaccines still require the use of animals to document that they are safe prior to release for sale. Many 
alternative safety tests have been developed or are currently in development but have not yet been validated for 
routine use. Workshop participants recommended that these should be given a high priority for further development 
and validation studies. The following vaccine safety tests were identified as priority for alternative test method 
activities: 
• Safety tests that require a lethal endpoint 
• Safety tests that require the largest number of animals and/or cause severe animal pain and distress 
• Safety tests that are highly variable and/or require frequent repeats 
• Safety tests that are associated with vaccines that have the largest number of lots produced annually 
• Safety tests that involve nonhuman primates 
Based on these criteria, the highest-priority vaccine safety testing methods recommended for further development 
and validation activities were: 
• The Vero cell assay for diphtheria toxoid to replace the guinea pig test for specific toxicity/reversal to toxicity 
• Histamine sensitization (HIST or HSA) for acellular pertussis (aP) vaccine: proposed humane endpoint (decrease 
in dermal temperature); in vitro replacement assays (enzyme-coupled HPLC, carbohydrate-binding assays, and 
cAMP assay) in development [29, 40, 41] 
• Transgenic mouse test for OPV, particularly for seed lots where the monkey neurovirulence test (MNVT) is still 
used 
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• Development of a functional in vitro assay for tetanus toxoid to replace the guinea pig test 
• Massively parallel sequencing (MPS) and other emerging technologies for OPV testing. (Participants noted that 
this would require substantial investment in the development of an adequate database with which to create a 
profile). 
 
Table 2: Examples of human vaccine safety tests that reduce and/or refine animal use 
 
Vaccine Product Alternative Method to Reduce/Refine 
Alternative Method 
References 
Traditional Safety 
Test 
Traditional Safety 
Test Reference 
Bacterins and Toxoids 
Whole-cell pertussis 
vaccine (Bordetella 
pertussis) 
Reduction in animal 
numbera
Hendriksen 2008 [43] Mouse weight gain test Ph. Eur. Monograph 
0161 [44]; WHO TRS 
941, 2007 [42] 
Acellular pertussis 
vaccine for whooping 
cough 
(Bordetella pertussis) 
Nonlethal endpoint HIST 
(refinement)b
Ph. Eur. 
Monographs1356 [45] 
and 1595 [46]; 
Arciniega et al. 
1998 [47]; 
Japanese Minimum 
Requirements for 
Biological Products, 
2006 [33]; Ochiai et al. 
2007 [48] 
Histamine 
sensitization test in 
mice  
Japanese Minimum 
Requirements for 
Biological Products, 
2006 [33]; WHO TRS 
878, 1998 [49] 
Viral Vaccines 
Oral polio vaccine 
(Poliovirus) 
Transgenic mouse modela 
(refinement) 
Ph. Eur. Monograph 
218 [50]; WHO TRS 
889, 1999 [51]; WHO 
TRS 904, 2002 [38] 
Nonhuman primate 
neurovirulence test 
Japanese Minimum 
Requirements for 
Biological Products, 
2006 [33]; WHO TRS 
800, 1989 [39] 
aPublished in the European Pharmacopoeia (Ph. Eur.). 
bIncluded in the European Pharmacopoeia as an option to lethal endpoint and subject to validation per product.  
 
5. Human vaccine post-licensing safety testing: reduction, refinement, and replacement alternative methods  
5.1. State of the science 
5.1.1. General safety test 
The general safety test (GST) is also known as the abnormal toxicity test (ATT) by the European Pharmacopoeia 
(Ph. Eur.) and the test for innocuity by the WHO. It is typically conducted using groups of approximately five mice 
and two guinea pigs administered the equivalent of one or more human doses of vaccine. A vaccine passes the test if 
none of the treated animals shows clinical signs of illness or adverse effects. The Ph. Eur. and the U.S. Code of 
Federal Regulations recently changed the requirement for GST/ATT by allowing the test to be omitted. Specifically, 
the Ph. Eur. states that  
the test can be waived by the competent authority in the interests of animal welfare when a sufficient 
number of consecutive production batches (generally 10) are found to comply with the test, thus 
demonstrating consistency of the manufacturing process, provided the vaccine is produced according to 
the principles of good manufacturing practice and quality assurance [36].  
Similarly, the U.S. Code of Federal Regulations states that  
a manufacturer may request an exemption from the general safety test by submitting information as part 
of a biologics license application submission or supplement to an approved biologics license application 
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establishing that because of the mode of administration, the method of preparation, or the special nature 
of the product a test of general safety is unnecessary to assure the safety, purity, and potency of the 
product or cannot be performed [35]. 
5.1.2. Specific toxicity tests 
An important part of the safety evaluation of vaccines that contain an inactivated toxin or inactivated virus (e.g., 
rabies) is a test to confirm that the inactivation has been effective. Examples of vaccines comprising or containing 
inactivated toxins include diphtheria, tetanus, aP, and whole-cell pertussis (wP) vaccines. Inactivation has 
historically been confirmed using tests in mice or guinea pigs with potential lethal outcomes. However, during the 
past decade, alternative methods have been introduced that reduce, refine, and replace the use of animals in these 
more specialized safety tests (Tables 1 and 2).  
Diphtheria is an upper respiratory tract illness caused by Corynebacterium diphtheriae, a facultative anaerobic 
Gram-positive bacterium. A highly sensitive in vitro Vero cell assay for determining the presence of residual 
diphtheria toxin and reversal to toxicity is currently approved for use in Europe and by the WHO to replace the 
guinea pig test. The in vitro assay is more sensitive than the animal model and is suitable for use during vaccine 
production to detect toxicity in pre-adsorbed toxoid bulks. A notable limitation of this assay is that it cannot be used 
for testing final vaccine lots of diphtheria vaccine adsorbed to aluminum adjuvant [32, 52, 53]. However, the assay 
is available and suitable for use as an in-process safety test. Workshop participants recommended further activities 
to bring about broader international acceptance and use of this assay where appropriate. 
Pertussis, also known as whooping cough, is a highly contagious disease caused by the bacterium Bordetella 
pertussis. For wP vaccines, the mouse weight gain (MWG) test for residual toxicity is recommended by the WHO 
[42]. Recently it has been proposed to reduce the number of mice required from 10 per group to 5 per group [43, 
44]. It should be noted that the Ph. Eur. now also includes a semiquantitative Chinese hamster ovary (CHO) cell 
assay that can be used to assess the presence of active pertussis toxin (PT) as an in-process control. However, due to 
technical limitations, it cannot be used for ensuring detoxification or on the final product containing an aluminum 
adjuvant.  
A number of other alternatives have also been investigated as replacements for the MWG test, including the 
HIST/HSA, the CHO cell assay mentioned above, and the leukocyte promotion (LP) test. For example, Straaten-van 
de Kappelle et al., [54] concluded that HSA, CHO, or LP test might identify wP residual toxicity more effectively 
than the MWG test.  
In the late 1970s, concerns about the side effects associated with wP vaccines prompted the development of aP 
vaccines. The aP vaccines, which contain up to five purified pertussis antigens, are less reactogenic than wP 
vaccines, but have been shown to confer adequate protection to vaccinees. One of these antigens, PT, is included in 
its chemically detoxified form in all U.S.-licensed vaccines that contain an aP component [Arciniega 2011]. The 
HIST, a lethal challenge assay, is the required test that measures the residual PT toxicity and the possible reversion 
of toxoid to toxin in aP vaccines [29]. However, dermal measurement of body temperature reduction has been 
proposed as a nonlethal, humane endpoint to allow early termination of the study, thereby reducing animal pain and 
distress [48]. 
5.1.2.1. Neurovirulence 
A potential hazard associated with live attenuated strains is the possibility that they could regain virulence during 
vaccine manufacturing. Thus, vaccines derived from neurotropic viruses (e.g., poliovirus, mumps virus, Japanese 
encephalitis virus, yellow fever virus) are evaluated to ensure that they are free of residual neurotoxicity. 
Differences are seen among regional regulatory testing requirements for these vaccines with respect to performing 
the test on master seed lots, working seed lots, or final manufacturing lots; and whether histological sections must be 
reviewed. Historically, the test for neurovirulence has been performed using monkeys in the MNVT. However, 
progress has been made in the development of alternative methods for OPV with the introduction of an in vivo 
transgenic mouse neurovirulence model.  
Although animals are still used, the transgenic mouse model replaces the use of nonhuman primates for OPV 
neurovirulence testing. The mouse strain used expresses the human poliovirus receptor [55, 56], and protocols have 
been developed for use with poliovirus types 1, 2, and 3 [38, 51]. However, there are practical limitations due to the 
cost, availability, and increased training requirements associated with this model [57].  
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An entirely in vitro approach to neurovirulence testing of OPV is the mutant analysis by PCR and restriction 
enzyme cleavage (MAPREC) test, which uses molecular biology tools to identify single-base mutations associated 
with reversion to neurovirulence of poliovirus type 3 [58]. The MAPREC test has undergone extensive validation 
and is currently being used in conjunction with in vivo tests for poliovirus type 3 [38]. More recent efforts have been 
directed at its applicability to poliovirus type 1 and type 2. It has been approved as a screening test prior to in vivo 
testing, such that any vaccine that fails this test would not be further tested in animals. Although the MAPREC test 
quantifies individual mutations (one per serotype) at a few genomic loci, it does not detect other mutations that may 
contribute to neurovirulence. To overcome this shortcoming, the FDA Center for Biologics Evaluation and Research 
is investigating the usefulness of new technologies such as MPS for identifying and quantifying the mutational 
profile in OPV lots [30, 59] in order to monitor their genetic stability. 
5.1.2.2. Bacterial endotoxins 
Part of the required safety testing for vaccines is an evaluation for the presence of pyrogenic (fever-inducing) 
substances in each lot that is released. The traditional pyrogenicity test described by the Ph. Eur. [60] and the United 
States Pharmacopeia (USP) requires the use of three rabbits to detect increases in body temperature during 3 hours 
after injection of the vaccine. The most common pyrogenic substances are lipopolysaccharide (LPS) cell wall 
components of Gram-negative bacteria. In vitro alternatives to the rabbit test are accepted for Gram-negative 
endotoxins including the Limulus amoebocyte lysate test (LAL test, also known as the bacterial endotoxin test) [61]. 
The Ph. Eur. and the FDA accept the LAL test for vaccines to hepatitis A, Haemophilus influenzae type B, 
influenza, rabies, typhoid, and yellow fever [62]; however, the LAL test cannot detect non-LPS pyrogens such as 
any derived from Gram-positive bacteria. One additional limitation for vaccine pyrogen testing with the LAL test is 
the fact that aluminum hydroxide and certain proteins can interfere with the LAL test [63, 64]. Therefore, vaccines 
that contain such components often cannot be tested in the LAL test.  
Other in vitro pyrogenicity assays have been developed that employ human monocytes or monocytoid cell lines 
and measure the release of fever-inducing cytokines such as IL-1β, IL-6, and TNFα [65, 66]. These alternatives can 
be accepted in certain circumstances by regulatory authorities in the United States and Europe on a case-by-case 
basis, subject to product-specific validation [66, 67]. For some vaccines, the limitations of the currently available 
alternatives necessitate that the animal test for pyrogens still be performed for some vaccines (e.g., polysaccharide 
vaccines, and tick-borne encephalitis vaccines [62]). 
5.2. Knowledge gaps and priority research, development, and validation activities 
Advancing the prioritized vaccine safety tests from concept to regulatory acceptance and implementation will 
require substantial investment in basic research, time, and money. Participants identified a number of knowledge 
and data gaps that currently exist and the key research that is necessary to address these gaps: 
• Basic understanding of the in vivo and in vitro mode of action(s) of specific toxins  
• Relevance of the in vitro test to product safety (correlation with the current in vivo safety test) 
• Identification of interactions between toxin and other components in the final vaccine  
Participants noted that there is a need for assays (for diphtheria and PT, specifically) that provide a measurement 
of function such as toxin cell binding, cell entry, or enzymatic activity that can then be related to vaccine safety. 
However, varying national and international regulatory requirements can complicate the adoption of any new 
alternative assays. Therefore, a roadmap for development of alternatives was considered important to guide 
manufacturers through the process for approval. An important part would be guidance on how to meet the 
requirements for a safety testing waiver in each region. 
In discussing ways to address these gaps, participants considered the advantages provided by measurements that 
demonstrate consistency in manufacturing. They suggested ways to better apply these principles to vaccine safety 
testing to facilitate the reduction of animal use. The key issue of consistency emerged from the category of vaccines 
that are manufactured using new technology, as in the case of recombinant DNA (rDNA) vaccines. These vaccine 
products are manufactured in a consistent way, and the focus of quality control is on in-process monitoring rather 
than on final batch testing [68]. Increased in-process monitoring of existing vaccines can be accomplished using 
newer, more sensitive technologies, but it could also create new challenges in understanding the relevance of small 
changes that are identified.  
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Participants identified a number of product-specific research activities that should be considered high priorities to 
reduce, refine, and replace the use of animals in safety testing for these vaccines, including the following: 
• Refinement of the aP lethal-endpoint HIST/HSA by the use of a dermal temperature endpoint 
• Selection and validation of combined in vitro assays as replacement alternatives to HIST/HSA (e.g., enzyme-
linked HPLC, carbohydrate-binding assays, cAMP assay) 
• Use of the Vero cell assay to monitor diphtheria toxin inactivation 
• Development of a fully functional in vitro assay for tetanus toxin 
• Research to expand the use of the transgenic mouse model for OPV 
• Expanded validation efforts for the sequence-based approach to OPV neurovirulence safety  
• Development of alternatives to the MNVT for preclinical safety and lot release neurovirulence testing of mumps 
(and possibly measles) vaccines 
6. Achieving broader acceptance and use of 3Rs methods for human vaccine post-licensing safety testing  
Workshop participants discussed how to facilitate the broader acceptance of alternative vaccine safety tests. In 
addition to the more general efforts aimed at improving interaction, communication, and harmonization of 
international regulatory requirements, they saw a need for the targeted research efforts: 
• Improve collaborative work to facilitate validation of the Vero cell assay for diphtheria toxin 
inactivation/reversion 
• Organize international collaborative studies once a test is considered validated, in an effort to improve worldwide 
acceptance 
• Ensure that collaborations are maintained and fostered throughout the process 
• Discuss the barriers preventing OPV manufacturers from accepting the FDA- and WHO-approved test that uses 
transgenic mice as an alternative to the use of monkeys in the neurovirulence testing of OPV  
• Increase international coordination in developing new safety tests to avoid the need to perform multiple tests to 
fulfill the requirements for different countries  
• Encourage broader access to information that describes vaccine safety test methods that have been successfully 
implemented to reduce, refine, and replace the use of animals. For example, publication of testing methods, open 
online access to the USP and Ph. Eur. monographs, understanding that the USP does not have vaccine specific 
monographs 
• Task focused work groups, such as the ICCVAM Interagency Biologics Working Group, with specific challenges 
as they arise 
7. Other issues to be addressed to facilitate the 3Rs in human vaccine post-licensing safety testing  
The workshop highlighted the following additional actions needed to either advance specific alternative vaccine 
safety testing methods or impact the general application of the 3Rs to post-licensing vaccine safety testing: 
• Harmonize and mutually recognize alternative test methods using the 3Rs principles 
• Clearly delineate the validation requirements for any new test method for acceptability to regulatory bodies 
around the world 
• Acknowledge, within the scientific community, that a 3Rs method may not agree with the current method when 
that test method is of questionable relevance (e.g., MNVT for OPV). Results of the “new” and the “old” method 
may not need to agree completely for an acceptable validation; however, there must be assurances that safety will 
be equivalent or better than that provided by the existing method 
• Delineate the role of international organizations (e.g., WHO, ICH) in facilitating the 3Rs and developing a 
framework to facilitate advances at the global level (recognizing that the ICH does not have vaccine specific 
guidance) 
• Accept that some validation studies using large numbers of animals may be required in some cases to provide the 
necessary information for new method acceptance 
• Address whether the GST/ATT/innocuity test for human vaccines can be replaced worldwide with principles of 
manufacturing consistency 
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• Address whether any replication by National Control Laboratories of in vivo safety testing performed by 
manufacturers can be eliminated (note: FDA and Health Canada regulations do not require replication of testing 
performed by manufacturers). Participants noted that proven consistency of production would be required before 
implementation on a case-by-case basis 
• Establish interaction and information exchange between human and veterinary stakeholders to provide a means 
of sharing best practices and facilitate adoption of 3Rs methods 
Participants also discussed the need for incentives for manufacturers and/or the academic research community 
that could speed up the development, validation, and implementation of 3Rs methods in post-licensing vaccine 
safety testing. Suggestions for regulatory authorities to consider included (1) offering fast-track regulatory review 
and (2) providing a fee waiver for biologics license application or a license supplement when an alternative method 
is included in the application. 
Participants also emphasized the need for funding opportunities to further research and development and 
validation efforts, referring specifically to the NICEATM–ICCVAM nominations and submissions process as an 
example.  
8. Discussion  
This was the first international workshop in the United States to focus on the reduction, refinement, and 
replacement of animal use for potency and safety release testing of human and veterinary vaccines. A key 
accomplishment of the workshop was bringing together experts from industry, academia, and government in the 
areas of potency and safety testing for both human and animal vaccines. There was broad recognition among 
vaccine manufacturers, regulatory authorities, and participants that these workshops vastly improve information 
exchange not only between global regions but also between regulatory authorities in the same country. This 
interaction can accelerate the development of alternative methods once priorities are firmly established.  
Workshop participants addressed the state of the science of reduction, refinement, and replacement alternative 
methods for human vaccine post-licensing safety testing. They recommended priority research and other activities 
necessary to advance the development and/or implementation of these alternative methods. Participants highlighted 
the need for basic scientific research, product-specific research and validation efforts, and regulatory harmonization 
to advance the development, validation, and implementation of post-licensing vaccine safety test methods that 
reduce, refine (less or no pain and distress), and replace the use of animals. Similar to those identified at other 
session breakout groups, criteria for prioritization included assays with lethal endpoints, tests that use the largest 
number of animals and have the highest yearly lot production, tests that are highly variable, and those that cause the 
greatest pain and distress. Reducing the use of nonhuman primates in vaccine safety testing was highlighted as 
particularly important, and participants called for focused research on finding and implementing alternatives, not 
only for the MNVT for OPV, but to replace neurovirulence tests for mumps and measles.  
Advances have been recognized in the application of alternative vaccine safety tests, but participants identified 
specific vaccine safety tests that could attain wider acceptance and use by manufacturers with additional focused 
research, including the Vero cell assay for diphtheria toxin, the HST/HSA assay with body temperature endpoint for 
aP, and the transgenic mouse test for OPV. 
Specific research was considered necessary to address scientific knowledge gaps in our basic understanding of 
the mode of action of toxins and their interaction with other vaccine components. Participants recommended 
research to expand understanding of how the in vivo response in animals correlates with the in vitro assay and 
specific research to develop a fully functional in vitro assay for tetanus toxin. Recurring themes included the need 
for the following: 
• More open access to methods and information such as pharmacopoeial monographs 
• Increased sharing and dissemination of information among regulators, manufacturers, and the scientific 
community 
• International harmonization of requirements and specifications for test methods  
• Recommendation that the regulatory authorities consider various means to encourage the use of 3Rs approaches, 
including waiving user fees, direct funding of research, facilitation of collaborations among industry and the 
academic community, and organization of international collaborative studies  
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These general themes highlight the international consensus that exists for applying the 3Rs to vaccine safety 
testing. By building on and reaffirming these important conclusions and recommendations, the outcome of this 
international workshop will advance alternative methods for vaccine safety testing that will reduce, refine, and 
replace the use of animals while ensuring the quality and safety of human vaccines and the protection of human 
health, animal health, and the environment. 
9. Conclusions 
This workshop session reviewed the current status of human vaccine post-licensing safety testing. Participants 
identified research, development, and validation activities necessary to further advance testing methods and 
strategies that would eliminate or reduce the use of animals or result in more humane treatment of animals. 
Workshop participants strongly agreed that increasing our understanding of the mode of action of toxins and 
focusing on efforts to replace the use of nonhuman primates in post-licensing vaccine safety testing will have the 
greatest impact toward advancing the use of alternative methods in this area. It was recommended that experts at the 
WHO, FDA, and Ph. Eur. could play a role in guiding wider acceptance and use of the transgenic mouse 
neurovirulence test for OPV.  
Workshop participants stressed the need for increased international harmonization, acknowledging that it is the 
key to advancing the use of 3Rs alternatives in vaccine potency and safety testing. Workshop participants also 
agreed that the continued interaction of the human and veterinary global vaccine communities could facilitate and 
expedite the unified goal of replacing animals for vaccine post-licensing safety testing. 
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